Clinical Trial Update: Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial of radiopharmaceutical 225Ac-SS0110 in extensive-stage small cell lung cancer and Merkel cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• 225Ac-SS0110

Snippet

Sponsor: Ariceum Therapeutics GmbH | Conditions: Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED